AMENDMENTS TO THE CLAIMS

Claims 1 to 28 (cancelled)

Claim 29 (currently amended)

A carbohydrate peptide conjugate ~~comprising a dendrimeric poly-lysine carrier enabling multiple epitopes B and T to be covalently attached thereto, wherein said carbohydrate peptide conjugate~~ is selected from the group consisting of the conjugates of the following formulae



(B4-T4-M)



(B2-T2-M)



(B8-T8-M)



(B4-T4-M)

wherein:

- B denotes a structurally defined carbohydrate moiety which is a tumor antigen, or a derivative thereof, containing B epitope other than a ~~sailoside~~ sialoside, or several identical or different B epitopes;
- T denotes a peptide comprising one $CD4^+$ T epitope or several identical or different T-epitopes;
- K denotes a lysine ~~from 1 to 13~~ residue;
- n is an integer from 1 to 13;
- m is an integer from 1 to 9; and

wherein the B and T groups are covalently attached to the poly-lysine carrier.

Claim 30 (previously presented)

A conjugate of claim 29 wherein the carbohydrate moiety is galactosyl.

Claim 31 (currently amended)

A conjugate of claim 29 which comprises 3 lysine residues, at least 2 $CD4^+$ T cell epitopes, which may be the same or different, linked to the NH_2 ends of 2 of the lysine residues and 4 α-galactosyl-N-acetyl-Serinc residues.

Claim 32 (previously presented)

A conjugate of claim 29 wherein the carbohydrate moiety is a galactosyl residue and is substituted with a glycosyl residue.

Claims 33 – 34 (cancelled)

Claim 35 (cancelled)

Claims 36 – 37 (cancelled)

Claim 38 (previously presented)

A conjugate of claim 29 wherein the carbohydrate is selected from the group consisting of Tn antigen, di-Tn antigen, Tri-Tn antigen, T^* antigen and hexa-Tn antigen.

Claim 39 (previously presented)

A pharmaceutical composition comprising the conjugate of claim 29 and a suitable carrier and adjuvant.

Claim 40 (previously presented)

A vaccine comprising the conjugate of claim 29.

Claim 41 (cancelled)

Claim 42 (previously presented)

An immunogenic composition comprising at least one carbohydrate peptide conjugate of claim 29 wherein said composition is capable of increasing the survival of a tumor bearing human or animal.

Claim 43 (currently amended)

An immunogenic composition comprising at least one carbohydrate conjugate of claim 42 wherein said conjugate comprises different carbohydrate antigens ~~to induce more efficient anti-tumor immunity against cancers~~.

Claim 44 (currently amended)

A method of inducing an immune response to at least one member of the group consisting of B-cells and $\underline{CD4^+}$ T-cells in a human or animal body, wherein the conjugate of claim 29 is administered to said human or animal body.

Claims 45 (cancelled)

Claim 46 (cancelled)

Claim 47 (previously presented)

A method of vaccination of a human or animal body wherein the conjugate of claim 29 is administered to said human or animal body.